Franck Audemar

405 total citations
11 papers, 66 citations indexed

About

Franck Audemar is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Franck Audemar has authored 11 papers receiving a total of 66 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Hepatology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Franck Audemar's work include Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Colorectal Cancer Treatments and Studies (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Franck Audemar is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Colorectal Cancer Treatments and Studies (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Franck Audemar collaborates with scholars based in France, Switzerland and Austria. Franck Audemar's co-authors include Laurent Mineur, Faïza Khemissa, Thomas Aparicio, François Ghiringhelli, Marion Thibaudin, Julie Blanc, Pierre-Luc Etienne, Mathieu Baconnier, Éric François and Michel Rivoire and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Hepatology and Annals of Surgical Oncology.

In The Last Decade

Franck Audemar

8 papers receiving 66 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Franck Audemar France	6	41	39	28	16	9	11	66
Yuki Nakagami Japan	7	36 0.9×	16 0.4×	27 1.0×	26 1.6×	11 1.2×	17	82
Toshio Otsuji Japan	5	60 1.5×	56 1.4×	33 1.2×	39 2.4×	5 0.6×	9	93
Hanneke van der Wijngaart Netherlands	5	28 0.7×	11 0.3×	19 0.7×	11 0.7×	11 1.2×	18	60
M Zivanovic Serbia	5	43 1.0×	37 0.9×	44 1.6×	42 2.6×	20 2.2×	10	111
Sabela Recalde Spain	5	41 1.0×	10 0.3×	22 0.8×	9 0.6×	12 1.3×	14	58
Imane H. El Dika United States	4	40 1.0×	17 0.4×	13 0.5×	16 1.0×	6 0.7×	12	56
Xuetao Shi China	6	22 0.5×	38 1.0×	10 0.4×	23 1.4×	12 1.3×	18	86
Brian Kim-Poh Goh Singapore	4	22 0.5×	43 1.1×	16 0.6×	34 2.1×	5 0.6×	4	62
Fariborz Mansour-Ghanaei Iran	2	16 0.4×	20 0.5×	14 0.5×	18 1.1×	7 0.8×	2	64
Marie Terroir-Cassou-Mounat France	6	19 0.5×	18 0.5×	10 0.4×	26 1.6×	9 1.0×	9	99

Countries citing papers authored by Franck Audemar

Since Specialization

Citations

This map shows the geographic impact of Franck Audemar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franck Audemar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franck Audemar more than expected).

Fields of papers citing papers by Franck Audemar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franck Audemar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franck Audemar. The network helps show where Franck Audemar may publish in the future.

Co-authorship network of co-authors of Franck Audemar

This figure shows the co-authorship network connecting the top 25 collaborators of Franck Audemar. A scholar is included among the top collaborators of Franck Audemar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franck Audemar. Franck Audemar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Boilève, Alice, Franck Audemar, Samuel Le Sourd, et al.. (2025). Treatment Intensification with Hepatic Arterial Infusion Chemotherapy in Patients with Liver-Only Colorectal Metastases Still Unresectable After Systemic Induction Chemotherapy: Exploratory Findings From a Prematurely Closed Multicenter Randomized Phase II Study: SULTAN UCGI 30/PRODIGE 53 (NCT03164655). Annals of Surgical Oncology. 33(2). 1460–1469.

Taı̈eb, Julien, Simon Pernot, Caroline Pétorin, et al.. (2025). 5-FU + Naliri, gemcitabine plus nab-paclitaxel or both regimens given sequentially for first line treatment of metastatic pancreatic ductal adenocarcinoma: A randomized phase II comparative study (FUNGEMAX-PRODIGE 61).. Journal of Clinical Oncology. 43(16_suppl). 4184–4184.

Pernot, Simon, Olivier Pellerin, Laurent Mineur, et al.. (2022). Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. Digestive and Liver Disease. 54(3). 324–330. 6 indexed citations

Boilève, Alice, Aline Maillard, Mathilde Wagner, et al.. (2020). Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy – a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol. BMC Cancer. 20(1). 74–74. 12 indexed citations

Limagne, Emeric, Marion Thibaudin, Julie Blanc, et al.. (2020). Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma. Cancers. 12(6). 1429–1429. 12 indexed citations

Boige, Valérie, Jean‐Pierre Pignon, Mathilde Wagner, et al.. (2019). PRODIGE 53-UCGI 30 (SULTAN): A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy.. Journal of Clinical Oncology. 37(15_suppl). TPS3619–TPS3619.

Lopez‐Crapez, Evelyne, Antoine Adenis, Simon Thézenas, et al.. (2018). FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial.. Journal of Clinical Oncology. 36(15_suppl). 3548–3548. 5 indexed citations

Khemissa, Faïza, J.-P. Bronowicki, Jean–Marc Perarnau, et al.. (2018). Results of the Phase II randomized French trial PRODIGE 21 comparing sorafenib vs pravastatin vs sorafenib and pravastatin vs best supportive care for the palliative treatment of HCC in CHILD B cirrhotic patients. Journal of Hepatology. 68. S195–S195. 7 indexed citations

Ychou, Marc, Michel Rivoire, Simon Thézenas, et al.. (2018). Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial.. Journal of Clinical Oncology. 36(15_suppl). 3535–3535. 6 indexed citations

10.

Ychou, Marc, Michel Rivoire, Simon Thézenas, et al.. (2016). FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial.. Journal of Clinical Oncology. 34(15_suppl). 3512–3512. 14 indexed citations

11.

Audemar, Franck, et al.. (1999). [Left branch portal vein thrombosis associated with hyperhomocysteinemia].. PubMed. 23(12). 1388–91. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact